转录性失调是阿尔特梅西尼的作用机制的基础
bioRxiv : the preprint server for biology
|September 5, 2025
概括
艺术素
科学领域:
- 疟疾和寄生虫学
- 分子生物学与遗传学
- 药物发现和开发
背景情况:
- 素是一种重要的抗疟疾药物,但其确切的作用机制尚不清楚.
- 抗素疟疾寄生虫的出现需要更深入地了解其功能以开发更好的治疗方法.
- 识别新的药物点对于抗击疟疾和克服耐药性至关重要.
研究的目的:
- 阐明阿尔特米西宁抗疟疾作用的分子机制.
- 研究素治疗对寄生虫的转化机制和tRNA修改的影响.
- 鉴定寄生虫表谱中的潜在漏洞,
主要方法:
- 进行比较的转录组学 (RNA测序) 和蛋白质组学,以分析素治疗的P. falciparum.
- 液体染色学合质谱法 (LC-MS) 用于对tRNA的修饰性核糖体进行量化.
- 对基因表达变化的分析,重点是子使用和tRNA修饰途径.
主要成果:
- 在不同转换的基因中,阿尔特米西宁治疗引发了显著的代码使用模式的变化.
- 在37位的一种特定的tRNA修饰,N-threonyl-carbamoyladenosine (t6A) 在艺术素应激下被发现是低修饰的.
- 在阿尔特米西宁治疗后,观察到PfSua5酶的降低,该酶对生物合成至关重要.
结论:
- 阿尔特米西宁的作用方式包括破坏tRNA修饰途径,特别影响t6A.
- 在P. falciparum*中,tRNA表转录组代表了潜在的治疗脆弱性.
- 这些发现为开发下一代抗疟疾药物克服抗药性提供了新的途径.
更多相关视频
10:22Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
9.0K
08:22IR-TEx: An Open Source Data Integration Tool for Big Data Transcriptomics Designed for the Malaria Vector Anopheles gambiae
Published on: January 15, 2020
6.2K
相关概念视频
MicroRNAs
21.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
RNA Stability
31.6K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
31.6K
Riboswitches
8.0K
Riboswitches are non-coding mRNA domains that regulate the transcription and translation of downstream genes without the help of proteins. Riboswitches bind directly to a metabolite and can form unique stem-loop or hairpin structures in response to the amount of the metabolite present. They have two distinct regions – a metabolite-binding aptamer and an expression platform.
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
8.0K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
